1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Digestive tract conditions
  5. Diarrhoea and vomiting

Bile acid malabsorption: colesevelam

Evidence summary [ESUOM22] Published: 29 October 2013

  • Advice
  • Information for the public
  • Key points from the evidence
  • Overview for healthcare professionals
  • Relevance to NICE guidance programmes
  • Intervention and alternatives
  • Evidence review: efficacy
  • Evidence review: safety
  • Evidence review: economic issues
  • Evidence strengths and limitations
  • Summary for patients
  • References
  • Development of this evidence summary
  • Appendix: Search strategy and evidence selection
  • About 'Evidence summaries: unlicensed or off-label medicines'
Download (PDF)

Advice

  • Next

Relevance to NICE guidance programmes

Relevance to NICE guidance programmes

The use of colesevelam for bile acid malabsorption is not appropriate for referral for a NICE technology appraisal and it is not currently planned into any other work programme.

NICE has issued diagnostic guidance on SeHCAT (tauroselcholic [75selenium] acid) for the investigation of diarrhoea due to bile acid malabsorption in people with diarrhoea-predominant irritable bowel syndrome (IBS-D) or Crohn's disease without ileal resection (NICE diagnostics guidance 7). This recommends SeHCAT for use in research for diagnosing bile malabsorption in these groups.


  • Next